Eleusis, a clinical-stage life science company, completed the acquisition of Kalypso Wellness Centers, a provider of ketamine infusion therapies in the United States, for $21m. “Eleusis is transforming psychedelics into medicines across a broad range of unmet needs, starting with major depressive disorder where conventional psychedelic drug therapies may be undermined by problematic tolerability, reliability, accessibility and affordability. Overcoming these challenges has been the focus of our scientists and clinicians since 2013, and the acquisition of Kalypso underscores our commitment to accelerating the development of broadly accessible psychedelic drug therapies for patients in urgent need of treatment alternatives,” Shlomi Raz, Eleusis Chairman and CEO.